Otsuka Holdings Co., Ltd. (OTSKF)
OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 0.00 |
| Open | 45.73 |
| Bid | 54.46 x 40000 |
| Ask | 59.46 x 40000 |
| Day's range | 45.73 - 45.73 |
| 52-week range | 35.91 - 45.73 |
| Volume | |
| Avg. volume | 169 |
| Market cap | 29.902B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 24.99 |
| EPS (TTM) | 1.58 |
| Earnings date | 29 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | 0.80 (2.02%) |
| Ex-dividend date | 27 Dec 2024 |
| 1y target est | N/A |
ZacksIonis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
- Zacks
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
Business WireRecor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy
PALO ALTO, Calif., November 10, 2023--Recor Medical, Inc. announces the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation system for the treatment of hypertension.
© 2024 Yahoo. All rights reserved.